Comment on

• Effects of the luteinizing hormone-releasing hormone agonist leuprolide on lipoproteins, fibrinogen and plasminogen activator inhibitor in patients with benign prostatic hyperplasia.

  Eri LM, Urdal P, Bechensteen AG. Eri LM, et al. J Urol. 1995 Jul;154(1):100-4. J Urol. 1995. PMID: 7539852 Clinical Trial.
• Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: a multicenter study.

  Fawzy A, Braun K, Lewis GP, Gaffney M, Ice K, Dias N. Fawzy A, et al. J Urol. 1995 Jul;154(1):105-9. J Urol. 1995. PMID: 7539853 Clinical Trial.
• Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double-blind, placebo-controlled, dose-response multicenter study.

  Gillenwater JY, Conn RL, Chrysant SG, Roy J, Gaffney M, Ice K, Dias N. Gillenwater JY, et al. J Urol. 1995 Jul;154(1):110-15. J Urol. 1995. PMID: 7539854 Clinical Trial.
• Prostatic histology in secondary transurethral resection of the prostate.

  Jønler M, Bruskewitz RC. Jønler M, et al. J Urol. 1995 Jul;154(1):119-22. J Urol. 1995. PMID: 7539855
• Randomized double-blind study comparing the efficacy of terazosin versus placebo in women with prostatism-like symptoms.

  Lepor H, Theune C. Lepor H, et al. J Urol. 1995 Jul;154(1):116-8. J Urol. 1995. PMID: 7776406 Clinical Trial.
• Symptoms of the transurethral resection syndrome using glycine as the irrigant.

  Olsson J, Nilsson A, Hahn RG. Olsson J, et al. J Urol. 1995 Jul;154(1):123-8. J Urol. 1995. PMID: 7776407